FDA Approves FENTANYL TRANSDERMAL — SpecGx LLC
SpecGx LLC announced the FDA approval of the Fentanyl Transdermal ANDA (App # ANDA077154) on February 9th, potentially expanding generic competition for the potent opioid pain patch and putting downward pressure on market share for branded players.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day